BioArctic AB (publ) (STO:BIOA.B)
Sweden
· Delayed Price · Currency is SEK 245.80
-13.60 (-5.24%)
Feb 21, 2025, 5:29 PM CET
BioArctic AB Revenue
In the year 2024, BioArctic AB had annual revenue of 257.35M SEK, down -58.22%. BioArctic AB had revenue of 101.24M in the quarter ending December 31, 2024, with 1,269.72% growth.
Revenue
257.35M
Revenue Growth
-58.22%
P/S Ratio
84.57
Revenue / Employee
2.41M
Employees
107
Market Cap
21.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 257.35M | -358.64M | -58.22% |
| Dec 31, 2023 | 616.00M | 386.56M | 168.49% |
| Dec 31, 2022 | 229.43M | 203.77M | 794.02% |
| Dec 31, 2021 | 25.66M | -39.54M | -60.64% |
| Dec 31, 2020 | 65.21M | -217.74M | -76.95% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.03B |
| Getinge AB | 34.76B |
| Sectra AB | 3.14B |
| Camurus AB | 1.87B |
| Medicover AB | 23.97B |
| Vitrolife AB | 3.61B |
| Elekta AB | 17.72B |
| Vimian Group AB | 4.29B |
BioArctic AB News
- 5 days ago - Leqembi® sales reaches €200 million - first sales milestone achieved - PRNewsWire
- 27 days ago - FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US - Benzinga
- 27 days ago - FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US - PRNewsWire
- 5 weeks ago - FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US - PRNewsWire
- 2 months ago - Leqembi® approved in Mexico - PRNewsWire
- 3 months ago - Leqembi® launched in South Korea - PRNewsWire
- 3 months ago - CHMP issues positive recommendation for approval of lecanemab in the EU - PRNewsWire
- 3 months ago - Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion - PRNewsWire